BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
1535 results:

  • 1. Fusobacterium periodonticum BCT protein targeting glucose metabolism to promote the epithelial-mesenchymal transition of esophageal cancer cells by lactic acid.
    Guo X; Wan P; Shen W; Sun M; Peng Z; Liao Y; Huang Y; Liu R
    J Transl Med; 2024 Apr; 22(1):401. PubMed ID: 38689341
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
    Sang Y; Min R; Huang T; Zhang J
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-akt pathway activation.
    Du R; Xiao N; Han L; Guo K; Li K; Chen Z; Zhang H; Zhou Z; Huang Y; Zhao X; Bian H
    Sci Rep; 2024 Apr; 14(1):9167. PubMed ID: 38649770
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
    Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
    Ma J; Xu J; Zhang X; Quan J
    Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic Prostate cancer.
    Uzelac M; Xin R; Ongkeko WM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/akt signaling pathway in nasopharyngeal carcinoma.
    Xu K; Jiang P; Chen Z; Gu X; Zhang T
    Pathol Res Pract; 2024 Apr; 256():155264. PubMed ID: 38518731
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation.
    Hu S; Li S; Xu Y; Huang X; Mai Z; Chen Y; Xiao H; Ning W; Gaus S; Savkovic V; Lethaus B; Zimmerer R; Acharya A; Ziebolz D; Schmalz G; Huang S; Zhao J; Hu X
    Phytomedicine; 2024 Jun; 128():155488. PubMed ID: 38493718
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PHA-665752's Antigrowth and Proapoptotic Effects on HSC-3 Human Oral cancer Cells.
    Yadav AK; Wang S; Shin YM; Jang BC
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474118
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.
    Wang WP; Shi D; Yun D; Hu J; Wang JF; Liu J; Yang YP; Li MR; Wang JF; Kong DL
    World J Gastroenterol; 2024 Feb; 30(6):565-578. PubMed ID: 38463028
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Potential targets of diosgenin for the treatment of oral squamous cell carcinoma and their bioinformatics and transcriptional profiling analyses.
    Xiao Y; Xu B; Li X; Ding T; Zhao W; Nie X; Mu J; Xiao Z; Wang Q; Ren Q; Zhang E
    Steroids; 2024 May; 205():109393. PubMed ID: 38458369
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. GSG2 promotes thyroid cancer via stabilizing AURKB and activating akt pathway.
    Zhang F; Huang C
    Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology: Ixeris sonchifolia Induces Hepatocellular Carcinoma Apoptosis via the PI3K/akt Pathway.
    Liu BJ; Guan YY; Qiao LX; Zhang JM; Li AJ; Yang PX; Gao YX; Chen DX; Wang CX; Wu J
    J Ethnopharmacol; 2024 Jun; 327():117994. PubMed ID: 38437889
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Differential modulation of PI3K/akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
    Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
    Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.
    Chang Z; Jia Y; Gao M; Song L; Zhang W; Zhao R; Yu D; Liu X; Li J; Qin Y
    Biol Direct; 2024 Mar; 19(1):19. PubMed ID: 38429756
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Pretreatment periodontitis is predictive of a poorer prognosis after esophagectomy for esophageal cancer.
    Nozaki S; Sato Y; Takano H; Nomura K; Wakita A; Liu J; Nagaki Y; Sasamori R; Sasaki Y; Takahashi T; Igarashi H; Konno Y; Fukuda M; Minamiya Y
    Esophagus; 2024 Apr; 21(2):120-130. PubMed ID: 38376617
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Artesunate-loaded solid lipid nanoparticles resist esophageal squamous cell carcinoma by inducing Ferroptosis through inhibiting the akt/mTOR signaling.
    Xia Y; Tang Y; Huang Z; Ke N; Zheng Y; Zhuang W; Zhang Y; Yin X; Tu M; Chen J; Wang Y; Huang Y
    Cell Signal; 2024 May; 117():111108. PubMed ID: 38369266
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
    Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
    Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 77.